Alcami, a contract development and manufacturing organisation (CDMO), announced on Tuesday that it has completed Phase II of its cGMP biostorage facility situated in Amherst, New Hampshire.
The company's 104,000 square feet area is now completely operational and supports various cGMP storage requirements. The whole site covers a total area of 160,000 square feet.
The company is planning to complete phase III in the first quarter of 2023 and will add an additional 56,000 square feet of new capacity.
SCG releases SCG101 late-breaking clinical data in HBV-related hepatocellular carcinoma
Genprex signs new research agreement with University of Pittsburgh to advance diabetes gene therapy
AstraZeneca and Daiichi Sankyo's Enhertu shows strong results in early-stage breast cancer trial
Adcentrx's ADRX-0706 granted US FDA Fast Track designation to treat advanced cervical cancer
Ajinomoto and RIBOMIC announce successful extension of nucleic acid aptamer pharmacokinetics
AstraZeneca secures EU approval for Calquence combo as first-line treatment in mantle cell lymphoma
Odylia Therapeutics undertakes gene replacement therapy project for NPHP1 retinal dystrophy
Phanes Therapeutics doses first patient in peluntamig-atezolizumab combination clinical study
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Nutshell Therapeutics' NTS071 p53 allosteric reactivator cleared for US clinical trial